Form 4: TransMedics Group CEO Waleed Hassanein Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold 30,000 shares of common stock at a weighted average price of $130.07, according to a recent SEC filing.
Summary
- On May 6, 2024, Waleed H. Hassanein, CEO of TransMedics Group, Inc., exercised stock options to acquire 30,000 shares of common stock at a price of $13.28 per share.
- Simultaneously, Hassanein sold 30,000 shares of common stock at a weighted average price of $130.07.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Hassanein directly owns 61,643 shares of TransMedics Group, Inc.
- Hassanein also indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust.
- He also holds options to purchase 148,000 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The market will likely interpret this as a standard executive compensation activity.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units, which vest over time.
- Rule 10b5-1 trading plans are a common tool used by executives at publicly traded companies to manage their stock holdings and avoid insider trading concerns.
- The size and frequency of these transactions are typical for CEOs of companies with similar market capitalizations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the transactions mitigates any significant concerns.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 09/06/2023 | Date of establishment of the Rule 10b5-1 trading plan |
| 05/06/2024 | Date of stock option exercise and share sale |
| 05/08/2024 | Date of SEC filing |
| 02/22/2026 | Date the option is fully vested |
| 02/22/2032 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.